Press Releases

Oasmia announces a prospectus regarding admission to trading of new shares

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) has prepared a prospectus regarding the admission to trading of the 22,948,535 shares in the Company that were issued in the directed issue which was an...

Oasmia Pharmaceutical Strengthens its Management Team and Organization

To increase resources and its business development function, Oasmia has employed Anette Sjödin as Executive Vice President to focus on commercialization and business development. The organization is further strengthened...

Oasmia has completed a directed share issue of approximately 165 MSEK

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the Company has carried out a placing of shares in the Company, through a directed issue of 22,948,535 shares, corresponding to ap...

Oasmia Pharmaceutical AB (publ)

Interim report for the period May 2018 – January 2019

NOTICE OF EXTRAORDINARY GENERAL MEETING IN OASMIA PHARMACEUTICAL AB (PUBL)

THE SHAREHOLDERS OF OASMIA PHARMACEUTICAL AB (PUBL) ARE HEREBY GIVEN NOTICE OF THE EXTRAORDINARY GENERAL MEETING ON TUESDAY 19 MARCH 2019, AT 14.00 P.M., AT THE OFFICES OF THE COMPANY AT VALLONGATAN 1, 752 28 UPPSALA. TH...

Change in the number of shares and votes in Oasmia Pharmaceutical AB (publ)

Oasmia Pharmaceutical AB (publ) (”Oasmia” or ”Company” or “Group”) on 18 April 2018 issued a convertible loan with a total nominal amount of MSEK 26. In total circa MSEK 7 of the convertible loan has during J...

Oasmia Pharmaceutical AB’s (publ, ”Oasmia”) decision to cancel the extraordinary general meeting on January 25, 2019

The proposition on a new board of directors in Oasmia presented by Arwidsro Investment AB and Per Arwidsson (jointly “Arwidsro”) only a short period before the planned general meeting does not comply with Nasdaq Stoc...

Oasmia announces that the extraordinary general meeting 25 January 2019 is cancelled

Oasmia Pharmaceutical AB (publ) (“Oasmia” or the ”Company”) hereby announces that the board of directors of the Company has resolved to cancel the extraordinary general meeting which was to be held 25 January 201...

European Medicines Agency validates Oasmia Pharmaceutical AB’s application to add efficacy data to the approved Apealea® product information

Efficacy data from sub-group analysis for Apealea show significant advantage with regards to progression free survival in patients with first relapse

Clarification from the Board of Directors and Management of Oasmia Pharmaceutical AB (publ), “Oasmia” due to Per Arwidsson’s and Arwidsro Investment AB’s request for convening an Extraordinary General Meeting

In 2017 and 2018, Oasmia has had a number of successful developments. Oasmia is currently in a phase where it has positive momentum with many ongoing activities.